MedTrace Logo

PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets

NCT04920292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-20

No results posted yet for this study

Summary

The study evaluates the pharmacokinetics (PK), safety and tolerability of oxfendazole, after administration as a tablet formulation in healthy male and female participants.

Conditions

  • Filariasis

Interventions

DRUG

Oxfendazole

Oxfendazole is a benzimidazole anthelminthic drug.

DRUG

Placebo

The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Sponsors & Collaborators

  • Ifakara Health Institute

    collaborator OTHER

  • Drugs for Neglected Diseases

    collaborator OTHER

  • Swiss Tropical & Public Health Institute

    lead OTHER

Principal Investigators

  • Daniel Paris · Swiss TPH

  • Said Jongo · Ifakara Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2022-11-07
Completion
2022-11-14

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920292 on ClinicalTrials.gov